News for Immunome, Inc. (IMNM)

- IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies.

Kelly Dilts will leave Dollar General in August.

Mark Mason shared insights on the company’s performance and client outlook.

Immunome, Inc. (the ”œCompany”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an

Immunome, Inc. (IMNM) granted inducement stock options to 8 new employees under Nasdaq Rule 5635(c)(4). The grants consist of 125,500 shares with an exe

On June 3, 2025, Jean Bienaime, a Director at Immunome Inc (IMNM), purchased 5,000 shares of the company. Following this transaction, the insider now holds a to

[url="]Immunome,[/url] Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann

[url="]Immunome,[/url] Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann

By the end of March 31, 2025, Immunome (IMNM) reported a total of $317.3 million in cash, cash equivalents, and marketable securities. This figure reflects the

Immunome (IMNM) delivered earnings and revenue surprises of 21.21% and 28.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Revenue: Achieved $2.93 million, significantly surpassing the estimated $0.29 million.Net Loss: Reported a net loss of $41.6 million, an improvement from the $

Immunome (IMNM) reported a net loss of $41.6 million for Q1 2025, with cash and equivalents totaling $317.3 million as of March 31, 2025. The company is

Immunome (IMNM) is currently trading at a substantial discount, according to research by Piper Sandler. This assessment follows the announcement of a definitive

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why I rate IMNM stock a buy.

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that I

Immunome, Inc. (the ”œCompany”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! The ...

In the opening 90 minutes of the evening session, U.S. stock futures are up marginally – S&P500 is up 0.1% while Nasdaq 100 is up 0.2%. Earlier on Tuesday, Consumer Discretionary and Communications Services were the best performing sectors in the S&P500 – Google (GOOGL), Meta (META), and Netflix (NFLX) had over 1% gains among the mega-caps – while defensively-oriented Healthcare and Utilities underperformed. Investors have also shrugged the disappointing Consumer Confidence data with sentiment t

**media[577745]**